No Data
No Data
Unity Biotechnology Shares Are Trading Lower After the Company Announced 36-week Results From Its Phase 2b ASPIRE Clinical Trial.
Unity Biotechnology Explores Strategic Alternatives Post-ASPIRE Study
Express News | UNITY Biotechnology Inc - Company Estimates $3.7 Million Cash Expenses for Reduction in Force - SEC Filing
Express News | UNITY Biotechnology Inc - CEO, CFO, and Clo to Transition Into Consulting Roles
UNITY Biotechnology Announces Complete 36-Week Results From Phase 2b ASPIRE Clinical Trial Of Intravitreal UBX1325 In Patients With Diabetic Macular Edema
Express News | UNITY Biotechnology Inc - Board Approves Revised Operating Plan to Reduce Cash Burn